Skip to main content

Table 4 Treatment outcomes of patients with and without KDIGO 3 acute kidney injury, and with two different formulations of intravenous colistin

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

 

KDIGO 3 AKI

P-value

Intravenous colistin

 

Yes, n = 41

No, n = 154

Locolin®, n = 95

Colimycin®, n = 100

Ventilator days (Median, IQR)

36 (17–52)

22 (13–42)

0.036

28 (15–48)

24 (13–47)

0.048

ICU stay (days) (Median, IQR)

31 (19–47)

30 (20–51)

0.889

30 (19–47)

31 (21–54)

0.285

Hospital stay (days) (Median, IQR)

60 (38–94)

53 (31–80)

0.133

56 (35–87)

50 (29–76)

0.075

Mortality

Day 28

14 (34.1%)

62 (40.3%)

0.476

34 (35.8%)

42 (42%)

0.374

Discharge

28 (68.3%)

91 (59.1%)

0.283

56 (58.9%)

63 (63%)

0.562

  1. AKI acute kidney injury, ICU intensive care unit, IQR interquartile range